APA (7th ed.) Citation

Romeo, C., Joly, F., Ray-Coquard, I., El Kouri, C., Mercier-Blas, A., Berton-Rigaud, D., . . . You, B. (2019). Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial. Gynecologic Oncology, 152(1), 68. https://doi.org/10.1016/j.ygyno.2018.10.043

Chicago Style (17th ed.) Citation

Romeo, Clémence, et al. "Non-pegylated Liposomal Doxorubicin (NPLD, Myocet®) + carboplatin in Patients with Platinum Sensitive Ovarian Cancers: A ARCAGY-GINECO Phase IB-II Trial." Gynecologic Oncology 152, no. 1 (2019): 68. https://doi.org/10.1016/j.ygyno.2018.10.043.

MLA (9th ed.) Citation

Romeo, Clémence, et al. "Non-pegylated Liposomal Doxorubicin (NPLD, Myocet®) + carboplatin in Patients with Platinum Sensitive Ovarian Cancers: A ARCAGY-GINECO Phase IB-II Trial." Gynecologic Oncology, vol. 152, no. 1, 2019, p. 68, https://doi.org/10.1016/j.ygyno.2018.10.043.